期刊文献+

山东省2005-2011年血友病患者HCV HIV和梅毒感染情况

An investigation of HCV HIV and syphilis infection in hemophilia patients in Shandong,2005-2011
原文传递
导出
摘要 目的了解山东省血友病患者丙型肝炎病毒(Hepatitis C virus,HCV)、人类免疫缺陷病毒(Human immunodeficiency virus,HIV)和梅毒螺旋体(Treponema pallidum,TP)的感染情况。方法对2005-2011年山东省血友病诊疗中心确诊或治疗的628例血友病患者,采用酶联免疫吸附试验检测HCV、HIV和梅毒抗体,并根据年龄段进行分组,随机选择2 474例无偿献血者为正常对照。结果 628例血友病患者抗-HCV、抗-HIV和抗-TP的阳性率分别为9.6%(60/628)、0.6%(4/628)和0.2%(1/628),总感染率为10.4%(65/628)。0~19岁、20~39岁、40~77岁年龄段患者抗-HCV阳性率分别为3.3%、9.8%和20.5%。2 474例无偿献血者抗-HCV、抗-HIV和抗-TP的阳性率分别为0.4%(11/2 474)、0和0.2%(4/2 474),总感染率为0.6%(15/2 474)。结论血友病患者抗-HCV和抗-HIV阳性率明显高于无偿献血者,HCV感染与年龄密切相关。 Objective To better understand the infection status of HCV, HIV and syphilis in hemophilia patients. Methods Serum HCV, HIV and Treponerna pallidurn, (TP) antibodies were measured by ELISA in 628 hemophilia patients and 2 474 voluntaryblood donors. Results The positive rates of HCV, HIV and TP antibodies in 628 hemophilia patients were 9.6%, 0.6% and 0.2%, respectively, and the overall infection rate was 10.4% (65/628). The positive rates of HCV antibody in different age groups (0--19 years, 20--39 years and 40--77 years) were 3.3%, 9.8% and 20.5%, respectively. The positive rates of HCV, HIV and TP antibodies in 2 474 voluntary blood donors were 0.4%, 0.0% and 0. 2%, respectively, and the overall infection rate was 0. 6% (15/2 474). Conclusion The positive rates of HCV and HIV antibodies in hemophilia patients were much higher than those in voluntary blood donors,the rate of HCV infection in hemophilia patients was closely correlated with age.
出处 《中国艾滋病性病》 CAS 2012年第10期651-652,共2页 Chinese Journal of Aids & STD
关键词 血友病患者 丙型肝炎病毒 艾滋病病毒 梅毒 Hemophilia patients HCV HIV Syphilis
  • 相关文献

参考文献4

二级参考文献18

  • 1倪道明.血液制剂的病毒安全性问题及其对策[J].中国输血杂志,1993,6(4):222-226. 被引量:9
  • 2丁培芳,申法奎,李继红,马京香,刘德春.甲型血友病患者HBsAg和抗-HCV的初步检测[J].中国输血杂志,1996,9(4):209-209. 被引量:5
  • 3Alberti A, Benvegnu L. Management of hepatitis C. J Hepatol, 2003, 38(suppl 1)∶s1014-s1118.
  • 4Booth JCL, O'Grady J, Neuberger J. Clinical guidelines on the management of hepatitis C. Gut, 2001, 49(suppl 1)∶ s1-s21.
  • 5Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. Gut, 2002, 51∶864-869.
  • 6Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systemic review. Hepatology,2002,36(5 suppl 1)∶s135-s144.
  • 7Di Ciommo V, Russo P, Rava L, et al. Interferon alpha in the treatment of chronic hepatitis C in children: a meta-analysis. J Viral Hepat, 2003, 10∶210-214.
  • 8Fabrizi F, Dulai G, Dixit V, et al. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther, 2003, 18∶1071-1081.
  • 9Kjaergard LL, Krogsgaard K, Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ, 2001, 323∶1151-1155.
  • 10National Institute of Health Consensus Development Conference Panel Statement. Management of hepatitis C. Hepatology, 2002, 36(5 suppl 1)∶s3-s20.

共引文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部